Incyte Corp (INCY)
83.73
+1.39
(+1.69%)
USD |
NASDAQ |
Nov 08, 14:43
Incyte Revenue (Annual): 3.696B for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.696B |
| December 31, 2022 | 3.395B |
| December 31, 2021 | 2.986B |
| December 31, 2020 | 2.667B |
| December 31, 2019 | 2.159B |
| December 31, 2018 | 1.882B |
| December 31, 2017 | 1.536B |
| December 31, 2016 | 1.106B |
| December 31, 2015 | 753.75M |
| December 31, 2014 | 511.50M |
| December 31, 2013 | 354.95M |
| December 31, 2012 | 297.06M |
| December 31, 2011 | 94.46M |
| December 31, 2010 | 169.88M |
| December 31, 2009 | 9.265M |
| December 31, 2008 | 3.919M |
| Date | Value |
|---|---|
| December 31, 2007 | 34.44M |
| December 31, 2006 | 27.64M |
| December 31, 2005 | 7.846M |
| December 31, 2004 | 14.15M |
| December 31, 2003 | 41.20M |
| December 31, 2002 | 95.47M |
| December 31, 2001 | 219.26M |
| December 31, 2000 | 194.17M |
| December 31, 1999 | 157.00M |
| December 31, 1998 | 134.80M |
| December 31, 1997 | 90.00M |
| December 31, 1996 | 41.90M |
| December 31, 1995 | 12.20M |
| December 31, 1994 | 0.20M |
| December 31, 1993 | 0.30M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
2.159B
Minimum
2019
3.696B
Maximum
2023
2.980B
Average
2.986B
Median
2021
Revenue (Annual) Benchmarks
| Syndax Pharmaceuticals Inc | -- |
| Merck & Co Inc | 60.12B |
| Pfizer Inc | 58.50B |
| Biomarin Pharmaceutical Inc | 2.419B |
| Allogene Therapeutics Inc | 0.095M |